drugset / Trial / NCT01076699

A Four Arm Study to Evaluate the Safety and Efficacy of 3 Different Doses of RVX-100 Versus Placebo in Subjects With Irritable Bowel Syndrome Accompanied by Diarrhea (IBS-D)

NCT01076699 ↗

Phase 2 Suspended 192 enrolled Revogenex, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine if RVX-100 is safe and effective in treating acute abdominal pain in patients with irritable bowel syndrome accompanied by diarrhea.

Timeline

Start
2010-03
Primary completion
2010-12
Completion
2011-03

Outcome

Outcome not reported

Stopped (Enrollment): “recruiting/enrolling participants has halted prematurely but potentially will resume Oct”

Drugs

EvaluationDrugModalityDoseRoute
Comparator RVX-100 Unknown 0.075 mg —
Comparator RVX-100 Unknown 0.125 mg —
Comparator RVX-100 Unknown 0.25 mg —